| Date | Title | Description |
| 27.09.2024 | Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders | Lundbeck presents results from two studies in Multiple System Atrophy at International Congress of Parkinson's Disease and Movement Disorders
Fri, Sep 27, 2024 14:00 CET Report this content
Lundbeck advances its commitment to addressing the... |
| 08.07.2024 | Danish pole position among best Nordic life science stocks in H1 | Danish pole position among best Nordic life science stocks in H1
Mon, Jul 08, 2024 07:45 CET Report this content
The first six months of 2024 have passed and it is time to swap the ergonomically designed office chair for a sunbed At BioStoc... |
| 21.03.2024 | Advances in Digitalization Presented at the 10th Annual Genedata Biopharma Partner Symposium | Digitalizing Biopharma R&D: The Genedata Biopharma Platform is the #1 enterprise software system for achieving operational excellence in biopharma R&D.
Leading scientific, IT, and business innovators in the biopharma industry showca... |
| 17.03.2024 | Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year | Economy Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
George Glover
2024-03-17T08:31:02Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
F... |
| 13.03.2024 | Transactions with shares and linked securities in Genmab A/S made by managerial employees and their closely associated persons | - |
| 13.03.2024 | Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in Genmab | - |
| 13.03.2024 | Passing of Genmab A/S’ Annual General Meeting | - |
| 17.04.2023 | Genmab and argenx Enter Partnership to Advance Antibody Therapies in Immunology and Oncology | Genmab A/S and argenx announced that Genmab and argenx have entered into a collaboration agreement to jointly discover, develop and commercialize novel therapeutic antibodies with applications in immunology, as well as in oncology therapeut... |
| 26.01.2022 | Genmab A/S : Supplier Code of Conduct | Genmab Global Supplier Code of Conduct
Introduction
Genmab is focused on the creation and development of innovative and differentiated antibody products, with the aim of improving the lives of cancer patients. At Genmab we seek to establish... |
| 12.01.2022 | Genmab A/S : Human Rights Policy | Human Rights Commitment
As a global biotechnology company committed to social responsibility and sustainability, Genmab strives to comply with all laws, regulations, and standards applicable to the conduct of its business.
While governments... |
| 13.12.2021 | Genmab A/S : Corporate Social Responsibility Policy | Corporate Social Responsibility Policy
Genmab is committed to building a sustainable and socially responsible biotech, one whose actions reliably benefits patients, stakeholders, and society as a whole.
Our approach to Corporate Social Resp... |
| 22.09.2021 | Genmab A/S : Investor Presentation - September 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
September 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward lookin... |
| 22.09.2021 | Genmab A/S : Articles of association dated September 21, 2021 – English | (Unauthorized English translation)
(September 21, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Co... |
| 18.08.2021 | Genmab A/S : Articles of Association dated August 17, 2021 – English | (Unauthorized English translation)
(August 17, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Compa... |
| 11.08.2021 | Genmab A/S : Investor Presentation - August 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
August 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking s... |
| 08.07.2021 | Genmab A/S : Articles of Association dated July 06, 2021 – English | (Unauthorized English translation)
(July 6, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Company ... |
| 01.07.2021 | Genmab A/S : Articles of Association dated June 22, 2021 – English | (Unauthorized English translation)
(June 22, 2021)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Company... |
| 11.06.2021 | GENMAB A/S
Genmab A/S : Investor Presentation - June 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
June 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking sta... |
| 05.05.2021 | GENMAB A/S
Genmab A/S : Investor Presentation - May 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
May 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking stat... |
| 27.04.2021 | Genmab A/S : Articles of association dated April 13, 2021 – English | (Unauthorized English translation)
(April 13, 2021) (II)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the C... |
| 27.04.2021 | GENMAB A/S
Genmab A/S : Articles of association dated April 13, 2021 – English | (Unauthorized English translation)
(April 13, 2021) (II)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 85
Name, Registered Office, Objects and Group Language
§ 1.
The name of the C... |
| 09.04.2021 | GENMAB A/S
Genmab A/S : Investor Presentation - April 2021 | Innovating
Antibodies,
Improving Lives
Investor Presentation
April 2021
© Genmab For Investor audience only. Not for public information or use. Not for promotional use.
Forward looking statement
This presentation contains forward looking st... |
| 30.03.2021 | NOVARTIS AG
Novartis : receives EU approval for Kesimpta® (ofatumumab), the first and only self-administered, targeted B-cell therapy for adult patients with relapsing multiple sclerosis | There are more than 1 million people living with multiple sclerosis (MS) in Europe1, Kesimpta® (ofatumumab) addresses the current unmet need for a high-efficacy disease-modifying therapy (DMT) that combines powerful efficacy and favorable s... |
| 23.02.2021 | GENMAB A/S
Genmab A/S : CSR Report 2020 - English | Corporate Social Responsibility 2020 Report
24 Risks Relating to CSR
Introduction & CEO Letter
Contents
2
3
4
5
6
8
Contents CEO Letter Highlights About Genmab
Our Commitment to Corporate Social Responsibility Our Response to COVID-19
E... |
| 23.02.2021 | Genmab A/S : Compensation Report 2020 | 1
Genmab Remuneration Report 2020
Compensation Report for 2020
Compensation Report for 2020,
Genmab A/S
CVR no. 2102 3884
LEI code 529900MTJPDPE4MHJ122
This Compensation Report for 2020 describes the details of the compensation of the Board... |
| 23.02.2021 | GENMAB A/S
Genmab A/S : Compensation Report 2020 | 1
Genmab Remuneration Report 2020
Compensation Report for 2020
Compensation Report for 2020,
Genmab A/S
CVR no. 2102 3884
LEI code 529900MTJPDPE4MHJ122
This Compensation Report for 2020 describes the details of the compensation of the Board... |
| 23.02.2021 | Genmab A/S : CSR Report 2020 - English | Corporate Social Responsibility 2020 Report
24 Risks Relating to CSR
Introduction & CEO Letter
Contents
2
3
4
5
6
8
Contents CEO Letter Highlights About Genmab
Our Commitment to Corporate Social Responsibility Our Response to COVID-19
E... |
| 21.12.2020 | Genmab A/S : Articles of association dated December 15, 2020 – English | (Unauthorized English translation)
(December 15, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 21.12.2020 | GENMAB A/S
Genmab A/S : Articles of association dated December 15, 2020 – English | (Unauthorized English translation)
(December 15, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 11.11.2020 | GENMAB A/S
Genmab A/S : Articles of association dated November 10, 2020 – English | (Unauthorized English translation)
(November 10, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 11.11.2020 | Genmab A/S : Articles of association dated November 10, 2020 – English | (Unauthorized English translation)
(November 10, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 71
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Com... |
| 15.10.2020 | GENMAB A/S
Genmab A/S : Articles of association dated October 07, 2020 – English | (Unauthorized English translation)
(October 7, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 70
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Compa... |
| 30.09.2020 | GENMAB A/S
Genmab A/S : Articles of association dated September 29, 2020 – English | (Unauthorized English translation)
(September 29, 2020)
Articles of Association
of
Genmab A/S
(CVR-nr. 21023884
Formerly A/S registration no.: 248.498)
Page 2 of 69
Name, Registered Office, Objects and Group Language
§ 1.
The name of the Co... |
| 21.08.2020 | J&J adds yet another multiple myeloma regimen to the Darzalex label as Sanofi rival jumps in | J&J’s third-line multiple myeloma blockbuster Darzalex got the FDA green light for a new regimen to take another swing at the blood cancer — this time, in a cocktail with carfilzomib and dexamethasone.
The combination ... |
| 04.05.2020 | New Darzalex formulation wins FDA approval; Israeli biotech plans $50M IPO | → During the Covid-19 crisis, drugs that must be administered in hospital settings or take hours to be infused are seeing delayed uptake as health care facilities are filled to the brim with coronavirus patients. Cancer d... |
| 13.03.2020 | CureVac’s Ingmar Hoerr tells us why he returned to take on a pandemic; NGM loses a president | Ingmar Hoerr
On Tuesday, Ingmar Hoerr stood up from his seat at the head of CureVac’s board of directors meeting in Frankfurt, Germany and walked out the door.
For 18 years, Hoerr had led the company he founded, stewardin... |
| 29.05.2019 | Denmark’s Genmab files for $500M Nasdaq listing in US | The company is looking to raise $500 million in its US market debut, according to the Form F-1. Morgan Stanley is the lead book runner, joined by BofA Merrill Lynch, Guggenheim Securities, Jefferies and RBC Capital Markets.
The company’s le... |
| 08.05.2017 | Building an orphan pipeline, Horizon Pharma bags PhIII-ready rare disease drug in $145M buyout | Timothy P. Walbert
Eight months after a little-known subsidiary group named River Vision Development Corp. won a breakthrough therapy designation for its lead drug for a rare eye disease, Horizon Pharma $HZNP has swooped... |
| 11.08.2016 | Start small, think big: Genmab racks up a bispecific development deal with HIV specialist Gilead | Genmab is on a roll. The biotech has inked another high-profile collaboration deal — this time with Gilead — that will put its bispecific antibody tech to work on HIV therapies.
The deal starts small, with Gilead handing ove... |
| 26.07.2016 | Protocols: Booming Moderna adds staff, new clinical program; Lilly boasts of R&D gains | As promised, fast-growing Moderna has moved its second program into clinical development. The mRNA specialist now has mRNA 1440 and mRNA 1851, infectious disease vaccine candidates, in early stage studies. And there ... |
| 30.04.2012 | GSK leukemia treatment Arzerra filed for regulatory approval in Japan | The U.S. Food and Drug Administration approved ofatumumab, now called Arzerra, in 2009. Arzerra is the first commercialized drug to emerge from Denmark-based Genmab’s drug pipeline. Britain-based GSK, which has its U.S. headquarters in Rese... |
| 11.04.2002 | Genmab and Paradigm Therapeutics announce major alliance on discovery targets for human an... | Genmab and Paradigm Therapeutics announce major alliance on discovery targets for human an...
11-04-2002
Copenhagen, Denmark 11 April, 2002.
..Genmab A/S and the privately owned Cambridge, UK based Paradigm Therapeutics Ltd today announced ... |
| - | GSK leukemia treatment Arzerra filed for regulatory approval in Japan | Leukemia treatment Arzerra, developed by GlaxoSmithKline (NYSE:GSK) and drug partner Genmab (CSE:GEN), has been submitted for approval in Japan.
Arzerra has currently received regulatory approval in the United States and Europe to treat chr... |
| - | Denmark’s Genmab files for $500M Nasdaq listing in US | A Danish drugmaker is looking to list its shares on the Nasdaq.
Copenhagen-based Genmab said Tuesday that it had filed a Form F-1 with the Securities and Exchange Commission for a potential offering of shares on the US market, wherein it wo... |
| - | Four innovations that may shape cancer treatment | While significant progress has been made in the treatment of cancer, there is still a long way to go. Cancer has been the second leading cause of death among Americans for almost a decade.1 This year in the United States alone, it is estima... |
| - | Transforming patients’ lives starts with innovating novel medicines and enabling access to them | It’s indisputable that developing new treatment options is a crucial component to helping people with cancer live better — but driving real, meaningful change requires much more than that.
While innovation in medicine is at an all-time high... |
| - | Bioqube Ventures launches Bioqube Factory Fund I | June 10th – Hasselt/Brussels, Belgium – Bioqube Ventures announces today the first closing of Bioqube Factory Fund I, a new early stage venture capital fund focused on the development of therapeutic assets and technology platforms in Europe... |
| - | European stocks close marginally lower as markets digest U.S. data and BOE hike; mining firms down 3% | This is CNBC’s live blog covering European markets. |
